Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction
NCT ID: NCT01444872
Last Updated: 2012-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
17 participants
INTERVENTIONAL
2011-08-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TRV120027
TRV120027 administered as an IV infusion
TRV120027
IV infusion
Normal Saline
Normal Saline administered as an IV infusion
Normal Saline
IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TRV120027
IV infusion
Normal Saline
IV infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Heart Failure
* Mild to moderate renal dysfunction
* Age 18- \<75
* Males and females (non-childbearing potential)
Exclusion Criteria
* Any other serious life threatening disease that may impair the interpretation of safety or efficacy data from the study as determined by the Investigator
* Allergy or clinically-significant intolerance to ARBs or ACE inhibitors
* Clinical signs or symptoms of acute decompensated heart failure
* Pregnant or lactating
18 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Trevena Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orlando Clinical Research Center
Orlando, Florida, United States
DaVita Clinical Research
Minneapolis, Minnesota, United States
Duke Clinical Research Unit
Durham, North Carolina, United States
New Orleans Center for Clinical Research
Knoxville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor's Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP120027.1002
Identifier Type: -
Identifier Source: org_study_id